Remune Interim Data Due In 2Q98
Immune Response's Phase III trial of its therapeutic vaccine for HIVinfection, Remune (gp120-depleted HIV-1 immunogen), will generate interim results in the second quarter of 1998. The data and safety monitoring panel for the trial met earlier this month and concluded that it should continue as no safety concerns had been raised. The interim analysis will provide data on the rate of progression to death, opportunistic infections and AIDS-related cancers with Remune and controls.
Other developments in 1998 should include the completion of a US Phase II study looking at Remune in combination with antiretroviral drugs (Glaxo Wellcome's zidovudine and lamivudine, and Merck & Co's indinavir), completion of a Phase II study in Thailand, an interim analysis of a US pediatric trial and a Phase II combination drug trial in Spain.
Immune Response notes that recent studies have shown that Remune can elicit chemokine and interferon gamma responses, in addition to its well-characterized activity on T cells.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze